« I never give up »
Patrizia Paterlini-Bréchot, Scientific Advisor of Rarecells Diagnostics and inventor of “ISET® Blood Cytopathology”, interviewed by Inspir’her. http://www.inspirher.fr/patrizia-paterlini-brechot/
Prof. Paterlini-Bréchot at Toulouse TEDx
Please find in the video below the speech of Prof. Patrizia Paterlini-Bréchot, Scientific Advisor of Rarecells Diagnostics at Toulouse TEDx introducing the ISET® Blood Cytopathology (english subtitles availables).
Prof. Patrizia Paterlini-Bréchot will participate at the 39th European Congress of Cytology
Prof. Paterlini-Brèchot will attend the round table on September 22nd at 14:24 with a presentation entitled: SINGLE CELL GENETIC ANALYSIS HELPS VALIDATING CYTOPATHOLOGICAL IDENTIFICATION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH CLEAR CELLS RENAL CARCINOMA Programme:
ISET® Cytopathology now available!
ISET® Blood Cytopathology test is now avalable at ISET® Lab. For more information, visit http://www.isetbyrarecells.com/en/find-iset/
Diagnosis of Circulating Cancer Cells (CCC) is Critical in Predictive Oncology
A key issue with cancers that continue to have lower patient survivability rates, such as lung cancer, cervical cancer and colorectal cancer, is that they are often not diagnosed until later stages. Many times this means that cancer is...
Isolation of Circulating Tumor Cells of All Types Without Loss is a Technical Challenge
Circulating Tumor Cells (CTCs) are cells from a primary tumor that shed into a patient’s bloodstream. These cells can often be detected years before a cancer reaches metastasis, the later stages of cancer in which it becomes more difficult...
Circulating tumor cells are present in blood for years before metastases develop
It is widely accepted that the earlier cancer is diagnosed, the more likely a patient is to survive. The problem with the deadliest forms of cancer, such as lung, colorectal or cervical cancer among others, is that patients often...
Maximizing patient outcome potential of Medicare’s Commitment to cover preventive CT scans for patients at-risk for lung cancer
As the U.S. Centers for Medicare & Medicaid Services (CMS) begins to fund lung-cancer screening using low-dose helical computerized tomography (CT) for those at high risk for lung cancer, the U.S. healthcare system is expected to spend approximately $2...
Q&A with Dr. Paul Hofman
In an interview on the study “Sentinel Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease,” lead author Paul Hofman, MD, discusses the patient population and the 5 patients who were diagnosed early...